Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and SG&A drove a $22.6M net loss, reflecting a strategic investment phase. The company maintains a robust $293.8M cash position, is guiding to $210–230M in 2025 revenue, and has ample runway to fund multiple late-stage launches. Nereus's differentiated mechanism and premium pricing potential face TAM and competitive risks; 2026 catalysts include Bysanti PDUFA and the Nereus launch. Jirapong Manustrong/iStock via Getty Images Thesis Vanda Pharmaceuticals Inc. ( VNDA ) has seen a quick run-up in stock price over the New Year. This is, of course, due to the FDA's approval of Nereus for the treatment of motion This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for i
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDAPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDAGlobeNewswire
- Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag DisorderPR Newswire
- Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 10/29/25 - Miss
VNDA
Sec Filings
- 1/9/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 12/31/25 - Form 8-K
- VNDA's page on the SEC website